










Core and Collaborative Development-Stage Programs

Eleven Programs Have Entered Development, Many More Are in Discovery Stage



TARGET INDICATION	COMPOUND (GENE TARGET)	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	DICERNA PRODUCT RIGHTS	PARTNER
Primary Hyperoxaluria 1, 2 & 3	Nedosiran (<i>LDHA</i>)					100% global	
Chronic Hepatitis B	RG6346 (<i>HBV</i>)					U.S. opt-in	
AAT Liver Disease	Belcesiran (<i>SERPINA1</i>)					100% U.S. (Alnylam ex-U.S. opt-in)	
Alcohol Use Disorder	DCR-AUD (<i>ALDH2</i>)					100% global	
Cardiometabolic	LY3561774 (<i>ANGPTL3</i>)					Milestone/royalty	
Cardiometabolic	LY3819469 (<i>LPA</i>)					Milestone/royalty	
Cardiometabolic	LY3849891					Milestone/royalty	
Complement-mediated	DCR-COMP1 (<i>C3</i>)					Milestone/royalty	
Complement-mediated	DCR-COMP2 (<i>CFB</i>)					Milestone/royalty	
Cardiometabolic	DCR-NOVO1					Opt-in to co-dev. and co-comm.	
Cardiometabolic	DCR-NOVO2					Opt-in to co-dev. and co-comm.	

Anticipated Timing:

IND filing for DCR-AUD expected mid-2021

IND filings for LY3819469 and LY3849891 are Lilly's responsibility and are anticipated in Q2'21 and Q1'22, respectively.

Dicerna intends to deliver IND-supporting packages to Alexion for DCR-COMP1 and DCR-COMP2 in Q4'21 and Q1'22, respectively; IND/CTA filings are the responsibility of Alexion and are at their discretion.

With 20+ discovery-stage programs in multiple tissues